1H MR spectroscopy using TE averaged PRESS: A more sensitive technique to detect neurodegeneration associated with Alzheimer's disease

Magnetic Resonance in Medicine

Volumn 53, Issue 4, 2005, Pages 777-782

  Hancu, Ileana ^a   Zimmerman, Earl A ^b   Sailasuta, Napapon ^c   Kurd, Ralph E ^c  

^a GE GLOBAL RESEARCH   (United States)

^b ALBANY MEDICAL CENTER   (United States)

^c GE HEALTHCARE   (United States)

Author keywords

Alzheimer's disease; MR spectroscopy; TE averaged PRESS (PRESS J)

Indexed keywords

DISCRIMINANT ANALYSIS; MAGNETIC RESONANCE; NEURODEGENERATIVE DISEASES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ALZHEIMER'S DISEASE; DISCRIMINANT FUNCTIONS; MR SPECTROSCOPY; N-ACETYL ASPARTATE; NEURODEGENERATION; RECEIVER OPERATING CHARACTERISTIC CURVES; SENSITIVE TECHNIQUES; STEPWISE DISCRIMINANT;

PRESSES (MACHINE TOOLS);

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEGENERATIVE DISEASE; DEMENTIA; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; RATING SCALE; ALGORITHM; ANALYSIS OF VARIANCE; BRAIN LEVEL; CASE CONTROL STUDY; DIFFERENTIAL DIAGNOSIS; DISCRIMINANT ANALYSIS; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ROC CURVE;

ASPARTIC ACID; CREATINE; DRUG DERIVATIVE; INOSITOL; N ACETYLASPARTIC ACID; N-ACETYLASPARTATE;

AGED; AGED, 80 AND OVER; ALGORITHMS; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ASPARTIC ACID; BRAIN CHEMISTRY; CASE-CONTROL STUDIES; CREATINE; DIAGNOSIS, DIFFERENTIAL; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; ROC CURVE;

EID: 16444378671     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrm.20419     Document Type: Article

References (19)

1. Kantarci K, Xu Y, Shiung MM, O'Brien PC, Cha RH, Smith GE, Ivnik RJ, Boeve BF, Edland SD, Kokmen E, Tangalos EG, Petersen RC, Jack Jr CR. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 2002;14:198-207.
2. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003;226:315-336.
3. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 2000;57:339-344.
4. Jack Jr CR, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62:591-600.
5. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001;56:592-598.
6. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003;160:2003-2011.
7. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993;187:433-437.
8. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995;195:65-72.
9. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000;13:129-153.
10. Kantarci K, Reynolds G, Petersen RC, Boeve BF, Knopman DS, Edland SD, Smith GE, Ivnik RJ, Tangalos EG, Jack Jr CR. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am J Neuroradiol 2003;24:843-849.
11. Hurd R, Sailasuta N, Srinivasan R, Vigneron DB, Pelletier D, Nelson SJ. Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn Reson Med 2004;51:435-440.
12. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
13. Wells 3rd WM, Viola P, Atsumi H, Nakajima S, Kikinis R. Multi-modal volume registration by maximization of mutual information. Med Image Anal 1996;1:35-51.
14. Kantarci K, Jack Jr CR, Xu YC, Campeau NG, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokmen E, Tangalos EG, Petersen RC. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 2000;55:210-217.
15. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
16. Christiansen P, Schlosser A, Henriksen O. Reduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease. Magn Reson Imaging 1995;13:457-462.
17. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994;32:110-115.
18. Martinez-Bisbal MC, Arana E, Marti-Bonmati L, Molla E, Celda B. Cognitive impairment: classification by 1H magnetic resonance spectroscopy. Eur J Neurol 2004;11:187-193.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.